Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics
- Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth
PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE:SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitive agreement.
Under its collaboration with Senseonics, Ascensia acquired exclusive global distribution rights for Eversense in 2020 and launched Eversense 365, the world's first and only one-year CGM system, in the U.S. in October 2024. PHC Holdings Corporation and its subsidiaries are collectively known as PHC Group.
As Eversense continues to grow, its go-to-market approach has increasingly departed from Ascensia's core blood glucose monitoring business. PHC Group, Ascensia, and Senseonics agree that unifying development, manufacturing, and distribution within Senseonics would enable Eversense to accelerate growth and realize its full potential faster than under the current structure. For PHC Group, this decision also aligns with its long-term business strategy (Value Creation Plan), which includes updating the company structure and portfolio to pursue operational efficiency.
Following the signing of a definitive agreement, most of the Eversense commercial team at Ascensia including Brian Hansen, President of CGM, who led the successful U.S. Eversense 365 launch, would transition to Senseonics. PHC Group and Ascensia plan to transfer commercial operations for Eversense to Senseonics and utilize Transition Service Agreements as needed while Senseonics establishes its global infrastructure. The companies anticipate minimal disruption for business partners, patients and providers.
Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia, commented: "We are very proud to have worked with Senseonics on commercializing Eversense and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them when we have a definitive agreement. PHC Group remains invested in Senseonics and will continue to explore additional growth opportunities in the diabetes space."
Tim Goodnow, President and Chief Executive Officer of Senseonics, commented: "Eversense is truly differentiated from any other CGM system on the market, and we believe now is the time to bring manufacturing and commercialization together to allow Senseonics to grow and remain responsive to the future needs of people with diabetes. We truly appreciate the partnership and investment that PHC Group and Ascensia have made in Senseonics, and we look forward to welcoming the talented commercial team and continuing to build momentum for Eversense 365."
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex and Mediford. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group's consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries and regions. https://www.phchd.com/global
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems and the exclusive global distribution partner for the Eversense® Continuous Glucose Monitoring Systems from Senseonics. These products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has around 1,400 employees and operations in 29 countries.
For further information, please visit the Ascensia Diabetes Care website at http://www.ascensia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250903537999/en/
Investor Relations & Corporate Communications Department
PHC Holdings Corporation
Julia Cottrill
Tel: +1 720 237 0891
Email: [email protected]